WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.
Under the terms of the agreement, Cubist will receive exclusive worldwide rights to research, develop and commercialize products generated from the collaboration. The collaborative research will focus on up to two GPCR drug targets to be selected by Cubist. For the first target, Heptares will receive $5.5 million (USD) upfront and up to approximately $4 million in research funding plus milestones and royalties. Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials. Further terms of the agreement are not disclosed.
Steve Gilman, Cubist Executive Vice President, Research & Development and Chief Scientific Officer said: "We are pleased to collaborate with Heptares, a recognized leader in the GPCR field, to pursue potential new GPCR drug candidates. This partnership underscores our commitment to develop a robust pipeline of novel products that address high unmet medical needs in patients with acute diseases.""We are very excited to work with Cubist, one of the fastest growing biopharmaceutical companies in the world and a commercial leader in the acute care therapeutics area," said Malcolm Weir, CEO of Heptares. "This agreement further demonstrates the strength of our strategy to extend the reach of our unique platform across the GPCR universe through partnerships with leading pharmaceutical and specialty companies, while advancing our own proprietary pipeline into clinical development." About G protein-coupled receptors (GPCRs)
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV